MAIA Biotechnology, Inc.

AMEX:MAIA

Biotechnology

Healthcare
$1.30 +3.41%

+$0.05 today

Market cap
$80.28M
Beta
0.24
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.87High $3.19

Volume 2.25M

Average 0.78M

MAIA Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

MAIA Biotechnology, Inc.AMEX: MAIA

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital dips below year-ago levels

Q1 FY2026 change in working capital of $619.6K fell 19.5% year over year, behind the +432.3% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +62.0% a year.

Context

  • Change in working capital increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -19.5% toward the trailing-twelve-month pace of +432.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$619.6K+114.3% QoQ
Last fiscal yearDec 2025
$1.5M+221.1% YoY
LTMMar 2026
$1.35M+432.3% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.5%——
1 year+221.1%——
3-year CAGR+62.0%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
1.5M USD
Year-over-year change
+221.1%
4-year CAGR
+7.4%

Change in Working Capital vs competitors

How MAIA compares with its peers on the latest reported figures

  • MAIA's LTM Mar 2026 change in working capital of $1.35M is the 4th largest of the 7 companies compared; the peer median is $92.5K.
  • Its year-over-year change of +432.3% is the 2nd highest of 6, against a peer median of +20.9%.
MAIA Competitors Peer median
Change in Working Capital for MAIA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$33.59M +63.3%—126.5%
ANVSAnnovis Bio, Inc.LTM Mar 2026$12.76M +682.7%——
VERUVeru Inc.LTM Mar 2026$3.71M +20.9%——
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$1.35M +432.3%+62.0%—
LTRNLantern Pharma Inc.LTM Mar 2026$197.17K -218.5%——
RNXTRenovoRx, Inc.LTM Mar 2026$185K -15.5%—12.4%
PYPDPolyPid Ltd.LTM Dec 2025$0 ———
Peer median (excluding MAIA) $92.5K+20.9%—69.5%

Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.58M)(15.77M)(19.77M)(23.25M)(22.4M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation2.72M2.32M3.09M1.91M2.63M
Change in Working Capital1.13M352.78K3.09M(1.24M)1.5M
Accounts Receivables0(269.4K)158.41K56.81K80.41K
Inventory00000
Accounts Payables805.52K211.35K471.9K(118.83K)519.72K
Other Working Capital320.23K410.83K2.46M(1.18M)899.19K
Other Non-Cash Items4.61M1M526.53K6.88M(579.4K)
Operating Cash Flow(4.12M)(12.1M)(13.07M)(15.7M)(18.84M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment7.43M0000
Common Stock Issued5.74M13.97M11.42M18.75M18.52M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities860.43K(1.5M)(2.15M)(578.1K)(617.13K)
Financing Cash Flow14.03M12.48M9.27M18.18M17.91M
Effect of Forex Changes0(4.43K)(117)(21.55K)(5.22K)
Net Change in Cash9.91M376.64K(3.8M)2.45M(943.27K)
Free Cash Flow(4.12M)(12.1M)(13.07M)(15.7M)(18.84M)

MAIA Biotechnology, Inc.

AMEX:MAIA

Intrinsic Alpha fair value

Locked

Current Price

$1.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.